Soumya Paul

Soumya Paul is CEO at Pentavalent Biosciences.

Articles

strigana/Stock.Adobe.com – image of magnifying class taking a close look at vials and syringes.

Platform-Specific Risk Assessment of SARS-CoV-2 Vaccines Using FMEA

Rajika Jindani ;Smritie Sheth;Soumya Paul;Anurag S. Rathore;Narendra Chirmule

February 2nd 2021

Amid the rush for a SARS-CoV-2 vaccine to deal with the COVID-19 pandemic, a robust risk assessment must be conducted, and mitigation strategies applied.

Latest Updated Articles

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

Published: September 11th 2024 | Updated: September 18th 2024

CPHI Pharma Award Finalists Announced for 2024

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Published: March 27th 2024 | Updated: June 28th 2024

AbbVie Acquires Landos Biopharma and Gets Full FDA Nod for ADC Product

Published: November 15th 2024 | Updated: November 20th 2024

Solving Challenges with AAV Aggregate Analysis Using a Novel Size Exclusion Particle to Determine CQAs

Published: October 28th 2024 | Updated: November 20th 2024

Cell-based phenotypic screening with Incucyte® Live-Cell Analysis Systems

Published: October 22nd 2024 | Updated: November 20th 2024

Optimizing cGMP Facility Design Space with a Hybrid Approach

Published: October 28th 2024 | Updated: November 20th 2024

Quantifying Chemotherapeutic Cytotoxicity in Glial Cells using AI-Driven Label-Free Cell Analysis

About Us

Advertise

Editorial Information

Do Not Sell My Personal Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777